Third-generation bisphosphonates for treatment of sensorineural hearing loss in otosclerosis

Otology and Neurotology

Volumn 33, Issue 8, 2012, Pages 1308-1314

  Quesnel, Alicia M ^a,b   Seton, Margaret ^c   Merchant, Saumil N ^a,b   Halpin, Christopher ^a,b   McKenna, Michael J ^a,b  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bisphosphonates; Otosclerosis; Sensorineural hearing loss

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; DRUG DERIVATIVE; ETIDRONIC ACID; IMIDAZOLE DERIVATIVE; RISEDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; AUDITORY THRESHOLD; BONE CONDUCTION; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; MALE; MIDDLE AGED; OTOSCLEROSIS; PERCEPTION DEAFNESS; PHYSIOLOGY; PURE TONE AUDIOMETRY; RETROSPECTIVE STUDY; SPEECH PERCEPTION; TREATMENT OUTCOME;

ADULT; AGED; AUDIOMETRY, PURE-TONE; AUDITORY THRESHOLD; BONE CONDUCTION; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; HEARING LOSS, SENSORINEURAL; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; OTOSCLEROSIS; RETROSPECTIVE STUDIES; SPEECH PERCEPTION; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84866612405     PISSN: 15317129     EISSN: 15374505     Source Type: Journal    
DOI: 10.1097/MAO.0b013e318268d1b3     Document Type: Article

References (32)

1. Ealy M, Smith RJ. Otosclerosis. Adv Otorhinolaryngol 2011;70: 122-9.
2. Chole RA, McKenna M. Pathophysiology of otosclerosis. Otol Neurotol 2001;22:249-57.
3. Cureoglu S, Baylan MY, Paparella MM. Cochlear otosclerosis. Curr Opin Otolaryngol Head Neck Surg 2010;18:357-62.
4. Topsakal V, Fransen E, Schmerber S, et al. Audiometric analyses confirm a cochlear component, disproportional to age, in stapedial otosclerosis. Otol Neurotol 2006;27:781-7.
5. Glorig AG, Gallo R. Comments on sensorineural hearing loss in otosclerosis. In: Schuknecht HF, ed. Otosclerosis. Boston, MA: Little, Brown, 1962:63-78.
6. Cruise AS, Singh A, Quiney RE. Sodium fluoride in otosclerosis treatment: review. J Laryngol Otol 2010;124:583-6.
7. Kennedy DW, Hoffer ME, Holliday M. The effects of etidronate disodium on progressive hearing loss from otosclerosis. Otolaryngol Head Neck Surg 1993;109(3 Pt 1):461-7.
8. Favus MJ. Bisphosphonates for osteoporosis. N Engl J Med 2010; 363:2027-35.
9. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19: 733-59.
10. Sakai O, Curtin HD, Hasso AN, Swartz JD. Otosclerosis and dysplasias of the temporal bone. In: Som PM, Curtin HD, eds. Head and Neck Imaging. 4th ed. St. Louis, MO: Mosby, 2002:1245-73.
11. Russell RG. Bisphosphonates: the first 40 years. Bone 2011;49: 2-19.
12. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52.
13. Halpin C. Measuring audiometric outcomes. In: Shin J, Hartnick C, Randolph G, eds. Evidence Based Otolaryngology. New York, NY: Springer, 2008:227-38.
14. Halpin C, Rauch SD. Using audiometric thresholds and word recognition in a treatment study. Otol Neurotol 2006;27:110-6.
15. Thornton AR, Raffin MJ. Speech-discrimination scores modeled as a binomial variable. J Speech Hear Res 1978;21:507-18.
16. Kelemen G, Linthicum FH Jr. Labyrinthine otosclerosis. Acta Otolaryngol Suppl 1969;253:1-68.
17. Kwok OT, Nadol JB Jr. Correlation of otosclerotic foci and degenerative changes in the organ of Corti and spiral ganglion. Am J Otolaryngol 1989;10:1-12.
18. McKenna MJ, Merchant Saumil N. Disorders of bone. In: Merchant SN, Nadol JB Jr, eds. Schuknecht's Pathology of the Ear. 3rd ed. Shelton, CT: People's Medical Publishing House, 2010.
19. Parahy C, Linthicum FH Jr. Otosclerosis: relationship of spiral ligament hyalinization to sensorineural hearing loss. Laryngoscope 1983;93:717-20.
20. Bretlau P, Causse J, Causse JB, Hansen HJ, Johnsen NJ, Salomon G. Otospongiosis and sodium fluoride. A blind experimental and clinical evaluation of the effect of sodium fluoride treatment in patients with otospongiosis. Ann Otol Rhinol Laryngol 1985;94(2 Pt 1):103-7.
21. Bretlau P, Salomon G, Johnsen NJ. Otospongiosis and sodium fluoride. A clinical double-blind, placebo-controlled study on sodium fluoride treatment in otospongiosis. Am J Otol 1989;10:20-2.
22. Shambaugh GE Jr, Scott A. Sodium fluoride for arrest of otosclerosis: theoretical considerations. Arch Otolaryngol 1964;80: 263-70.
23. Derks W, De Groot JA, Raymakers JA, Veldman JE. Fluoride therapy for cochlear otosclerosis? an audiometric and computerized tomography evaluation. Acta Otolaryngol 2001;121:174-7.
24. Causse JR, Causse JB. Clinical studies on fluoride in otospongiosis. Am J Otol 1985;6:51-5.
25. Russell RG. Bisphosphonates: the first 40 years. Bone 2011;49: 2-19.
26. Brookler KH, Tanyeri H. Etidronate for the the neurotologic symptoms of otosclerosis: preliminary study. Ear Nose Throat J 1997; 76:371-6, 9-81.
27. Novartis Pharmaceutical Corporation. Reclast [Full Prescribing Information]. East Hanover, New Jersey 2011. Available at: http://www.pharma.us. novartis.com/product/pi/pdf/reclast.pdf. Accessed August 15, 2011.
28. Warner Chilcott LLC. Actonel [Full Prescribing Information]. Rockaway, New Jersey 2011. Available at: http://www.actonel.com/global/prescribing- information.pdf. Accessed: August 15, 2011.
29. Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011;364: 1728-37.
30. Yasil S, Comlekci A, Guneri A. Further hearing loss during osteoporosis treatment with etidronate. Postgrad Med J 1998;74:363-4.
31. Reid IR, Mills DA, Wattie DJ. Ototoxicity associated with intravenous bisphosphonate administration. Calcif Tissue Int 1995;56: 584-5.
32. Boonen S, Ferrari S, Miller PD, et al. Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or longterm continuation on bone turnover and fracture risk-a perspective. J Bone Miner Res 2012;27:963-74.